FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Executive Summary
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa
You may also be interested in...
FDA’s First Chief Scientist Is Wake Forest Oncologist Frank Torti
FDA's new Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, FDA announced April 9
FDA’s First Chief Scientist Is Wake Forest Oncologist Frank Torti
FDA's new Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, FDA announced April 9
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects